Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)

Inclusion Criteria: * Written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures * Complete baseline documentation sent to GBG * Age of at least 18 and at most 45 years * Patients request to preserve ovarian function * Spontaneous and regular menstrual periods before study entry with FSH below 15 mlU/ml in follicular phase * Histologically confirmed primary breast cancer with the need for anthracycline-based chemotherapy * Steroid receptor (estrogen and progesterone) negative tumor (diagnosis according to hospital standard-procedures) * No clinical evidence of local recurrence or distant metastases. Complete staging work-up within 3 months prior to registration. All patients must have (bilateral) mammography or breast MRI, chest X-ray; other tests may be performed as clinically indicated * Karnofsky-Index \>80% * Life expectancy of at least 10 years, disregarding the diagnosis of cancer * Adequate organ function including normal red and white blood count, platelets, serum creatinine, bilirubin, and transaminases within normal range of the institution * Patients must be available for and compliant to treatment and follow-up. Patients registered on this trial must be treated and followed up at the participating center. Exclusion Criteria: * Known hypersensitivity reaction to the investigational compounds or incorporated substances * Prior cytotoxic treatment for any reason * Suspected (primary or secondary) ovarian insufficiency * Pregnant or lactating patients. Patients of childbearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to registration and must implement adequate non-hormonal contraceptive measures during study treatment; prior use of hormonal contraceptives has to be discontinued before first Goserelin injection * Other serious illness or medical condition that may interfere with the understanding and giving of informed consent and the conduct of the study * Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or carcinoma in situ of the uterine cervix) * Concurrent treatment with other experimental drugs or any other anti-cancer therapy * Concurrent treatment with sex hormones. Prior treatment must be stopped before study entry